Zydus Lifesciences gets USFDA’s tentative approval for Edaravone Injection

14 Mar 2024 Evaluate

Zydus Lifesciences has received tentative approval from the United States Food and Drug Administration (USFDA) to manufacture and market Edaravone Injection, 30 mg/100 mL (0.3 mg/mL), Single-Dose Vial, (RLD: RADICAVA).

Edaravone is used to treat a certain type of nerve disease called amyotrophic lateral sclerosis (ALS, also commonly called Lou Gehrig's disease). The drug will be manufactured at the group’s injectable manufacturing facility at Jarod, near Vadodara (India).

Edaravone Injection, 30 mg/100 mL (0.3 mg/mL), had annual sales of $19 million in the United States (IQVIA MAT Jan-24). The group now has 390 approvals and has so far filed over 460 ANDAs since the commencement of the filing process in FY 2003-04.

Zydus Lifesciences (formerly known as Cadila Healthcare) is an India-based pharmaceutical company.


Zydus Lifesciences Share Price

910.00 5.15 (0.57%)
16-Feb-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1699.75
Dr. Reddys Lab 1269.30
Cipla 1355.80
Zydus Lifesciences 910.00
Lupin 2220.50
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×